Published in Breast Cancer Res Treat on October 03, 2007
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. J Med Chem (2010) 2.12
Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol (2010) 1.13
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol (2009) 0.91
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res (2011) 0.89
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) (2011) 0.83
Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med (2012) 0.80
Stereological study of the effects of letrozole and estradiol valerate treatment on the ovary of rats. Clin Exp Reprod Med (2013) 0.80
Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design. EXCLI J (2013) 0.79
Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective. J Med Chem (2016) 0.78
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast Cancer Res Treat (2013) 0.78
Role of aromatase in sex-specific cerebrovascular endothelial function in mice. Am J Physiol Heart Circ Physiol (2014) 0.78
Acute inhibition of neurosteroid estrogen synthesis suppresses status epilepticus in an animal model. Elife (2016) 0.77
Letrozole increases ovarian growth and Cyp17a1 gene expression in the rat ovary. Fertil Steril (2012) 0.76
The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer. Chin Clin Oncol (2015) 0.75
Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. ACS Med Chem Lett (2014) 0.75
An effect of letrozole on gastric cancer? J Gastric Cancer (2011) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med (2005) 12.99
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst (2002) 9.65
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA (2000) 7.77
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Estrogen and the risk of breast cancer. N Engl J Med (2001) 4.39
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol (2001) 4.09
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol (1999) 3.74
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol (1998) 3.69
Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J (1996) 3.59
Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A (1997) 3.53
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol (2003) 3.51
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol (2000) 2.93
Biological aromatization of steroids. J Biol Chem (1959) 2.87
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol (2002) 2.87
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol (2001) 2.81
Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev (2005) 2.44
Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A (1994) 2.41
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer (2005) 2.32
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer (2003) 2.31
Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci U S A (1999) 2.19
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol (2002) 2.18
Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception (1996) 2.02
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol (2002) 1.83
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol (2008) 1.75
The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol (1999) 1.74
Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat (1994) 1.74
Human aromatase: gene resequencing and functional genomics. Cancer Res (2005) 1.71
The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology (1977) 1.71
Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res (1985) 1.70
Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol (2003) 1.66
A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab (1993) 1.60
Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab (1978) 1.53
Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab (1974) 1.51
Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol (2000) 1.46
Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene (2003) 1.43
The importance of local synthesis of estrogen within the breast. Steroids (1989) 1.42
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab (1993) 1.41
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer (1996) 1.40
A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res (1994) 1.39
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst (2004) 1.34
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res (1998) 1.31
Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab (1993) 1.31
Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab (1978) 1.27
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res (2005) 1.23
Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos (1997) 1.17
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol (1996) 1.15
A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol (1996) 1.15
Oestradiol synthesis by a human breast carcinoma. Lancet (1974) 1.15
Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol (1986) 1.14
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol (2001) 1.13
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res (1995) 1.12
In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione. Int J Cancer (1989) 1.10
The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab (2001) 1.09
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol (1998) 1.09
Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat (2005) 1.08
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res (1993) 1.06
MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.05
Aromatase activity in breast tissue. J Steroid Biochem Mol Biol (1991) 1.05
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res (2001) 1.05
Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol (1990) 1.03
Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res (1996) 1.03
Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer (1999) 1.02
Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res (1995) 1.01
Aromatase inhibitors--a triumph of translational oncology. N Engl J Med (2005) 1.00
Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer (1999) 0.99
The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat (1998) 0.99
Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer Clin Oncol (1985) 0.99
Human fatty marrow aromatizes androgen to estrogen. J Clin Endocrinol Metab (1980) 0.98
Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol (1990) 0.98
Steroid metabolism and oestrogen receptors in human breast carcinomas. Eur J Cancer Clin Oncol (1981) 0.96
6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem (1988) 0.96
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat (1999) 0.95
Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-alpha knock-out (ERKO)/Wnt-1 mice: implications for initiation of mammary tumors. Carcinogenesis (2001) 0.95
Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer (1999) 0.95
Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer (1999) 0.94
Aromatization of androstenedione by cultured human fibroblasts. J Clin Endocrinol Metab (1976) 0.94
Endogenous oestradiol-17beta concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. Eur J Cancer (1981) 0.93
The pharmacology of letrozole. J Steroid Biochem Mol Biol (2003) 0.93
The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol (1993) 0.92
The interconversion and aromatization of androgens by human adipose tissue. J Steroid Biochem (1979) 0.91
Mechanism of estrogen biosynthesis. Stereochemistry of C-1 hydrogen elimination in the aromatization of 2 beta-hydroxy-19-oxoandrostenedione. J Biol Chem (1981) 0.91
Aromatase inhibitors in breast cancer. Endocr Relat Cancer (2004) 0.91
Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos (2001) 0.90
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat (1994) 0.90
Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol (2003) 0.89
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin Cancer Res (2004) 0.88
Aromatization of androstenedione by human adult liver in vitro. J Clin Endocrinol Metab (1977) 0.87
The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J Steroid Biochem (1980) 0.87
The early days of letrozole. Breast Cancer Res Treat (2007) 0.75